Pneumococcal conjugate second or third-dose vaccines (PCVc) in Russia
Russia: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 95.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Russia, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Russia recorded 95.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025. That is the highest value across all 18 years on record.
That represents a change of up 1.1% on the previous year and up 9.2% over five years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Russia peaked at 95.0% in 2025 and was at its lowest, 0.0%, in 2008.
That places Russia 38th out of 194 countries with data for 2025, putting it in the top quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Russia, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 35.0% | — |
| 2017 | 69.0% | +97.1% |
| 2018 | 82.0% | +18.8% |
| 2019 | 85.0% | +3.7% |
| 2020 | 87.0% | +2.4% |
| 2021 | 89.0% | +2.3% |
| 2022 | 92.0% | +3.4% |
| 2023 | 93.0% | +1.1% |
| 2024 | 94.0% | +1.1% |
| 2025 | 95.0% | +1.1% |
Russia compared with similar countries
- Russia's 95.0% is above the median for high income countries, which is 91.0%, 1.0× the median. (63 countries reporting)
- Russia's 95.0% is above the median for Europe & Central Asia, which is 87.0%, 1.1× the median. (51 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 27.1% | 0.0% | 85.0% | 10 |
| 2020s | 91.7% | 87.0% | 95.0% | 6 |
Countries ranked near Russia
More health data for Russia
- Un projection of annual infant deaths, annual growth rate -0.7261 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.5159 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,176 deaths per 1,000 people (2090)
- Number of infants who die before age 1 957 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -3.34 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0224 units per person (2025)
- Population ages 00-04, male, annual growth rate -3.3 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Russia?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Russia was 95.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Russia?
- The highest recorded value was 95.0% in 2025.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Russia?
- The lowest recorded value was 0.0% in 2008.
- How does Russia rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Russia ranks 38th out of 194 countries with data for 2025.
- Where does this Russia data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).